Susan Clement Davies
Director/Board Member at SCANCELL HOLDINGS PLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jon Brett | M | 44 | 4 years | |
| Linda Durrant | F | 67 | 27 years | |
| Nagy Habib | M | 72 |
MiNA Therapeutics Ltd.
 MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | 16 years |
| Peter Bertram | M | 69 | 4 years | |
| Toni Haenninen | M | - | 1 years | |
| Robert Sebastian Habib | M | 39 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | - |
| Robert Lechler | M | - |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | 2 years |
| Daniel Edwards | M | - | 5 years | |
| Martyn Ratcliffe | M | 63 | - | |
| Sarah Cole | F | 45 | 13 years | |
| Peter Bains | M | 65 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | - |
| Ursula Ney | M | 72 | 5 years | |
| Sath Nirmalananthan | M | 38 | 1 years | |
| Martin Diggle | M | 62 | 5 years | |
| Robert Kopple | M | 81 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | - |
| Jean-Michel Cossery | M | 65 | 1 years | |
| Kieran Johnson | M | 55 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | - |
| Gur Roshwalb | M | 55 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | 4 years |
| Samantha Paston | M | - | 5 years | |
| Robert Matthew Miller | M | - | 4 years | |
| Helen Kuhlman | M | - | 3 years | |
| Laurie Clarke | M | - | 3 years | |
| Glen Clack | M | - | 3 years | |
| Christopher Barry Wood | M | 78 |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | - |
| Fayaz Master | M | - | - | |
| Mandeep Sehmi | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard Goodfellow | M | 74 | 23 years | |
| Stephen Franklin | M | 56 | 13 years | |
| Michael Lacey-Solymar | M | 61 | 11 years | |
| John Chiplin | M | 66 | 8 years | |
| Cliff Holloway | M | - | 3 years | |
| Sally Adams | M | 63 | - | |
| Alan J. Lewis | M | 78 | 4 years | |
| Barry Clare | M | 71 | 9 years | |
| Charles O'Bryan-Tear | M | 69 | - | |
| Marc d'Abbadie | M | - | 4 years | |
| David Chadwick | M | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 37 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Susan Clement Davies
- Personal Network
